Draco: l'ennesima sòla o cosa?
Draco: l'ennesima sòla o cosa?
Allora, io stavo per catalogare la cosa tra le "sòle yamamotiane", però c'è il fatto che il Massachusetts Institute of Technology ci mette la faccia, come dire: non è la Bocconi con quelle mezze seghe di Monti & C., questi sono tendenzialmente più seri...
HIVforum ha bisogno anche di te!
se vuoi offrire le tue conoscenze tecniche o linguistiche (c'è tanto da tradurre) o sostenere i costi per mantenere e sviluppare HIVforum, contatta con un PM stealthy e uffa2, oppure scrivi a staff@hivforum.info
se vuoi offrire le tue conoscenze tecniche o linguistiche (c'è tanto da tradurre) o sostenere i costi per mantenere e sviluppare HIVforum, contatta con un PM stealthy e uffa2, oppure scrivi a staff@hivforum.info
Re: Draco: l'ennesima sòla o cosa?
Questo è l'articolo pubblicato da "La Stampa":
Il farmaco che combatte tutti i virus
Da una ricerca del Mit l'annuncio di "Draco": sarebbe in grado
di contrastare le infezioni virali, da quelle lievi come il raffreddore a quelle gravi come Ebola o Aids
Quasi un secolo fa la scoperta della penicillina rivoluzionò il modo di curare le infezioni batteriche. Oggi un gruppo di ricercatori del Mit di Boston potrebbe avere trovato la cura per le infezioni virali, curando il raffreddore ma anche malattie molto più gravi, come l’Aids o l'Ebola.
Si tratterebbe del primo antivirale a largo spettro: a differenza degli antibiotici, gli antivirali sono pochi e molto specifici. I farmaci finora sperimentati colpiscono solo alcuni ceppi di virus, i quali mutano facilmente diventando resistenti alle cure. La nuova medicina, che si chiamerà «Draco», dovrà invece collaborare con i meccanismi di difesa già presenti nel corpo umano.
«I virus – ha spiegato Todd Rider, uno degli scienziati che hanno prodotto lo studio pubblicato su PLoS One – agiscono un po’ come l’Alien del film. Entrano in una cellula, si replicano al suo interno, e alla fine ne balzano fuori» . Quando si impadroniscono di una cellula, alcuni virus producono il cosiddetto Rna a doppio filamento, un acido che non viene prodotto dalle cellule sane. Ma il corpo umano possiede già delle difese antivirali naturali: produce infatti delle proteine che si legano all'Rna a doppio filamento impedendo al virus di replicarsi.
Il nuovo farmaco dovrebbe agire cercando le cellule che contengono l'Rna a doppio filamento, segno sicuro della presenza del virus: una volta trovato, dovrebbe ordinare alla cellula di autodistruggersi. La doppia arma, formata da quella naturale prodotta dall'organismo, insieme quella del farmaco, sarebbe perciò in grado di uccidere il virus. Rider assicura che il farmaco che non riscontra la presenza di Rna a doppio filamento viene espulso dal corpo senza alcun effetto collaterale.
Finora la nuova medicina sperimentata sui topi si è rivelata efficace contro 15 tipi di virus, tra cui quelli che causano la dengue febbrile emorragica e l'influenza H1N1, o suina, senza effetti tossici. «Il prossimo passo - spiega Rider - sarà verificare l'efficacia dell'antivirale su animali più grossi».
http://www3.lastampa.it/scienza/sezioni ... tp/436084/
Il farmaco che combatte tutti i virus
Da una ricerca del Mit l'annuncio di "Draco": sarebbe in grado
di contrastare le infezioni virali, da quelle lievi come il raffreddore a quelle gravi come Ebola o Aids
Quasi un secolo fa la scoperta della penicillina rivoluzionò il modo di curare le infezioni batteriche. Oggi un gruppo di ricercatori del Mit di Boston potrebbe avere trovato la cura per le infezioni virali, curando il raffreddore ma anche malattie molto più gravi, come l’Aids o l'Ebola.
Si tratterebbe del primo antivirale a largo spettro: a differenza degli antibiotici, gli antivirali sono pochi e molto specifici. I farmaci finora sperimentati colpiscono solo alcuni ceppi di virus, i quali mutano facilmente diventando resistenti alle cure. La nuova medicina, che si chiamerà «Draco», dovrà invece collaborare con i meccanismi di difesa già presenti nel corpo umano.
«I virus – ha spiegato Todd Rider, uno degli scienziati che hanno prodotto lo studio pubblicato su PLoS One – agiscono un po’ come l’Alien del film. Entrano in una cellula, si replicano al suo interno, e alla fine ne balzano fuori» . Quando si impadroniscono di una cellula, alcuni virus producono il cosiddetto Rna a doppio filamento, un acido che non viene prodotto dalle cellule sane. Ma il corpo umano possiede già delle difese antivirali naturali: produce infatti delle proteine che si legano all'Rna a doppio filamento impedendo al virus di replicarsi.
Il nuovo farmaco dovrebbe agire cercando le cellule che contengono l'Rna a doppio filamento, segno sicuro della presenza del virus: una volta trovato, dovrebbe ordinare alla cellula di autodistruggersi. La doppia arma, formata da quella naturale prodotta dall'organismo, insieme quella del farmaco, sarebbe perciò in grado di uccidere il virus. Rider assicura che il farmaco che non riscontra la presenza di Rna a doppio filamento viene espulso dal corpo senza alcun effetto collaterale.
Finora la nuova medicina sperimentata sui topi si è rivelata efficace contro 15 tipi di virus, tra cui quelli che causano la dengue febbrile emorragica e l'influenza H1N1, o suina, senza effetti tossici. «Il prossimo passo - spiega Rider - sarà verificare l'efficacia dell'antivirale su animali più grossi».
http://www3.lastampa.it/scienza/sezioni ... tp/436084/
HIVforum ha bisogno anche di te!
se vuoi offrire le tue conoscenze tecniche o linguistiche (c'è tanto da tradurre) o sostenere i costi per mantenere e sviluppare HIVforum, contatta con un PM stealthy e uffa2, oppure scrivi a staff@hivforum.info
se vuoi offrire le tue conoscenze tecniche o linguistiche (c'è tanto da tradurre) o sostenere i costi per mantenere e sviluppare HIVforum, contatta con un PM stealthy e uffa2, oppure scrivi a staff@hivforum.info
Re: Draco: l'ennesima sòla o cosa?
Questo è il lancio che appare sul sito del MIT:
New drug could cure nearly any viral infection
Researchers at MIT’s Lincoln Lab have developed technology that may someday cure the common cold, influenza and other ailments.
Anne Trafton, MIT News Office
Most bacterial infections can be treated with antibiotics such as penicillin, discovered decades ago. However, such drugs are useless against viral infections, including influenza, the common cold, and deadly hemorrhagic fevers such as Ebola.
Now, in a development that could transform how viral infections are treated, a team of researchers at MIT’s Lincoln Laboratory has designed a drug that can identify cells that have been infected by any type of virus, then kill those cells to terminate the infection.
The microscope images above show that DRACO successfully treats viral infections. In the left set of four photos, rhinovirus (the common cold virus) kills untreated human cells (lower left), whereas DRACO has no toxicity in uninfected cells (upper right) and cures an infected cell population (lower right). Similarly, in the right set of four photos, dengue hemorrhagic fever virus kills untreated monkey cells (lower left), whereas DRACO has no toxicity in uninfected cells (upper right) and cures an infected cell population (lower right). Enlarge image
In a paper published July 27 in the journal PLoS One, the researchers tested their drug against 15 viruses, and found it was effective against all of them — including rhinoviruses that cause the common cold, H1N1 influenza, a stomach virus, a polio virus, dengue fever and several other types of hemorrhagic fever.
The drug works by targeting a type of RNA produced only in cells that have been infected by viruses. “In theory, it should work against all viruses,” says Todd Rider, a senior staff scientist in Lincoln Laboratory’s Chemical, Biological, and Nanoscale Technologies Group who invented the new technology.
Because the technology is so broad-spectrum, it could potentially also be used to combat outbreaks of new viruses, such as the 2003 SARS (severe acute respiratory syndrome) outbreak, Rider says.
Other members of the research team are Lincoln Lab staff members Scott Wick, Christina Zook, Tara Boettcher, Jennifer Pancoast and Benjamin Zusman.
Few antivirals available
Rider had the idea to try developing a broad-spectrum antiviral therapy about 11 years ago, after inventing CANARY (Cellular Analysis and Notification of Antigen Risks and Yields), a biosensor that can rapidly identify pathogens. “If you detect a pathogenic bacterium in the environment, there is probably an antibiotic that could be used to treat someone exposed to that, but I realized there are very few treatments out there for viruses,” he says.
There are a handful of drugs that combat specific viruses, such as the protease inhibitors used to control HIV infection, but these are relatively few in number and susceptible to viral resistance.
Rider drew inspiration for his therapeutic agents, dubbed DRACOs (Double-stranded RNA Activated Caspase Oligomerizers), from living cells’ own defense systems.
When viruses infect a cell, they take over its cellular machinery for their own purpose — that is, creating more copies of the virus. During this process, the viruses create long strings of double-stranded RNA (dsRNA), which is not found in human or other animal cells.
As part of their natural defenses against viral infection, human cells have proteins that latch onto dsRNA, setting off a cascade of reactions that prevents the virus from replicating itself. However, many viruses can outsmart that system by blocking one of the steps further down the cascade.
Rider had the idea to combine a dsRNA-binding protein with another protein that induces cells to undergo apoptosis (programmed cell suicide) — launched, for example, when a cell determines it is en route to becoming cancerous. Therefore, when one end of the DRACO binds to dsRNA, it signals the other end of the DRACO to initiate cell suicide.
Combining those two elements is a “great idea” and a very novel approach, says Karla Kirkegaard, professor of microbiology and immunology at Stanford University. “Viruses are pretty good at developing resistance to things we try against them, but in this case, it’s hard to think of a simple pathway to drug resistance,” she says.
Each DRACO also includes a “delivery tag,” taken from naturally occurring proteins, that allows it to cross cell membranes and enter any human or animal cell. However, if no dsRNA is present, DRACO leaves the cell unharmed.
Most of the tests reported in this study were done in human and animal cells cultured in the lab, but the researchers also tested DRACO in mice infected with the H1N1 influenza virus. When mice were treated with DRACO, they were completely cured of the infection. The tests also showed that DRACO itself is not toxic to mice.
The researchers are now testing DRACO against more viruses in mice and beginning to get promising results. Rider says he hopes to license the technology for trials in larger animals and for eventual human clinical trials.
This work is funded by a grant from the National Institute of Allergy and Infectious Diseases and the New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases, with previous funding from the Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, and Director of Defense Research & Engineering (now the Assistant Secretary of Defense for Research and Engineering).
http://web.mit.edu/newsoffice/2011/antiviral-0810.html
New drug could cure nearly any viral infection
Researchers at MIT’s Lincoln Lab have developed technology that may someday cure the common cold, influenza and other ailments.
Anne Trafton, MIT News Office
Most bacterial infections can be treated with antibiotics such as penicillin, discovered decades ago. However, such drugs are useless against viral infections, including influenza, the common cold, and deadly hemorrhagic fevers such as Ebola.
Now, in a development that could transform how viral infections are treated, a team of researchers at MIT’s Lincoln Laboratory has designed a drug that can identify cells that have been infected by any type of virus, then kill those cells to terminate the infection.
The microscope images above show that DRACO successfully treats viral infections. In the left set of four photos, rhinovirus (the common cold virus) kills untreated human cells (lower left), whereas DRACO has no toxicity in uninfected cells (upper right) and cures an infected cell population (lower right). Similarly, in the right set of four photos, dengue hemorrhagic fever virus kills untreated monkey cells (lower left), whereas DRACO has no toxicity in uninfected cells (upper right) and cures an infected cell population (lower right). Enlarge image
In a paper published July 27 in the journal PLoS One, the researchers tested their drug against 15 viruses, and found it was effective against all of them — including rhinoviruses that cause the common cold, H1N1 influenza, a stomach virus, a polio virus, dengue fever and several other types of hemorrhagic fever.
The drug works by targeting a type of RNA produced only in cells that have been infected by viruses. “In theory, it should work against all viruses,” says Todd Rider, a senior staff scientist in Lincoln Laboratory’s Chemical, Biological, and Nanoscale Technologies Group who invented the new technology.
Because the technology is so broad-spectrum, it could potentially also be used to combat outbreaks of new viruses, such as the 2003 SARS (severe acute respiratory syndrome) outbreak, Rider says.
Other members of the research team are Lincoln Lab staff members Scott Wick, Christina Zook, Tara Boettcher, Jennifer Pancoast and Benjamin Zusman.
Few antivirals available
Rider had the idea to try developing a broad-spectrum antiviral therapy about 11 years ago, after inventing CANARY (Cellular Analysis and Notification of Antigen Risks and Yields), a biosensor that can rapidly identify pathogens. “If you detect a pathogenic bacterium in the environment, there is probably an antibiotic that could be used to treat someone exposed to that, but I realized there are very few treatments out there for viruses,” he says.
There are a handful of drugs that combat specific viruses, such as the protease inhibitors used to control HIV infection, but these are relatively few in number and susceptible to viral resistance.
Rider drew inspiration for his therapeutic agents, dubbed DRACOs (Double-stranded RNA Activated Caspase Oligomerizers), from living cells’ own defense systems.
When viruses infect a cell, they take over its cellular machinery for their own purpose — that is, creating more copies of the virus. During this process, the viruses create long strings of double-stranded RNA (dsRNA), which is not found in human or other animal cells.
As part of their natural defenses against viral infection, human cells have proteins that latch onto dsRNA, setting off a cascade of reactions that prevents the virus from replicating itself. However, many viruses can outsmart that system by blocking one of the steps further down the cascade.
Rider had the idea to combine a dsRNA-binding protein with another protein that induces cells to undergo apoptosis (programmed cell suicide) — launched, for example, when a cell determines it is en route to becoming cancerous. Therefore, when one end of the DRACO binds to dsRNA, it signals the other end of the DRACO to initiate cell suicide.
Combining those two elements is a “great idea” and a very novel approach, says Karla Kirkegaard, professor of microbiology and immunology at Stanford University. “Viruses are pretty good at developing resistance to things we try against them, but in this case, it’s hard to think of a simple pathway to drug resistance,” she says.
Each DRACO also includes a “delivery tag,” taken from naturally occurring proteins, that allows it to cross cell membranes and enter any human or animal cell. However, if no dsRNA is present, DRACO leaves the cell unharmed.
Most of the tests reported in this study were done in human and animal cells cultured in the lab, but the researchers also tested DRACO in mice infected with the H1N1 influenza virus. When mice were treated with DRACO, they were completely cured of the infection. The tests also showed that DRACO itself is not toxic to mice.
The researchers are now testing DRACO against more viruses in mice and beginning to get promising results. Rider says he hopes to license the technology for trials in larger animals and for eventual human clinical trials.
This work is funded by a grant from the National Institute of Allergy and Infectious Diseases and the New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases, with previous funding from the Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, and Director of Defense Research & Engineering (now the Assistant Secretary of Defense for Research and Engineering).
http://web.mit.edu/newsoffice/2011/antiviral-0810.html
HIVforum ha bisogno anche di te!
se vuoi offrire le tue conoscenze tecniche o linguistiche (c'è tanto da tradurre) o sostenere i costi per mantenere e sviluppare HIVforum, contatta con un PM stealthy e uffa2, oppure scrivi a staff@hivforum.info
se vuoi offrire le tue conoscenze tecniche o linguistiche (c'è tanto da tradurre) o sostenere i costi per mantenere e sviluppare HIVforum, contatta con un PM stealthy e uffa2, oppure scrivi a staff@hivforum.info
Re: Draco: l'ennesima sòla o cosa?
Secondo la teoria di London è che più ne hai (money) più ti fai sentire, e comunque anche tempo fa quando uscirono lanci precedenti a questo, mi lasciarono un po' perplessa. Vediamo magari qualcosa di buono lo ha, ho notato anche io che hanno ripreso la news, ora c'è solo d'aspettare e vedere per capire se sarà una sòla o no. Boh intanto però Siliciano si è rifatto vivo!! http://www.hivforum.info/forum/viewtopic.php?f=13&t=754
Re: Draco: l'ennesima sòla o cosa?
Ma su Draco già ne avevo chiesto conto con entusiasmo alla penultima visita con risata in faccia della dottoressa 
ma forti dubbi...
ma forti dubbi...-
thelondonsuede
- Messaggi: 742
- Iscritto il: domenica 18 marzo 2007, 18:19
- Località: SARANNO POI CAZZI MIEI UHUHUUHUHU
- Contatta:
Re: Draco: l'ennesima sòla o cosa?
Il todd rider institute sta cercando finanziamenti per i trial clinici sul progetto draco:
http://www.businessinsider.com/todd-rid ... 15-12?IR=T
https://riderinstitute.org/pages/draco
Assurdo che cerchi fondi dai privati , io ho fatto una donazione di 30 euro...nella speranza che cambi qualcosa
http://www.businessinsider.com/todd-rid ... 15-12?IR=T
https://riderinstitute.org/pages/draco
Assurdo che cerchi fondi dai privati , io ho fatto una donazione di 30 euro...nella speranza che cambi qualcosa